News and analysis on diagnostic technologies and applications.
The Australian firm will use the proceeds for R&D, expansion in China, and to fund the development of polygenic risk tests with TGen in the US.
The firm said that it may use some of the net proceeds to acquire or invest in complementary businesses and technologies.
The firm noted that its study showed strong performance data, including high sensitivity and high specificity, in providing results direct from blood.
The researchers said such a screening approach could capture younger individuals who don't regularly visit medical professionals.
The company will now be able to market the test, which algorithmically weighs molecular markers and clinical information, in all 50 US states.
